Craft

Northwest Biotherapeutics

Stock Price

$0.3

2024-10-29

Market Capitalization

$349.5 M

2024-10-29

Revenue

$1.4 M

FY, 2024

Northwest Biotherapeutics Summary

Company Summary

Overview
Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments and without the side effects of chemotherapy drugs. The Company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
Type
Public
Status
Active
Founded
1998
HQ
Bethesda, MD, US | view all locations
Website
https://www.nwbio.com/
Cybersecurity rating
ESG rating
30-39 out of 100|View all ESG data
Sectors

Key People

  • Les Goldman

    Les Goldman, Senior Vice President, Business Development

    LocationsView all

    1 location detected

    • Bethesda, MD HQ

      United States

      4800 Montgomery Ln

    Northwest Biotherapeutics Financials

    Summary Financials

    Revenue (Q1, 2025)
    $375.0K
    Net income (Q1, 2025)
    ($19.3M)
    Cash (Q1, 2025)
    $2.8M
    EBIT (Q1, 2025)
    ($17.3M)
    Enterprise value
    $430.5M

    Footer menu